Monopar Therapeutics MNPR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $11.75M-14.1% | $9.9M-23.8% | $15.89M+286% | $14.28M+221% | $13.68M+179% | ||
| $6.96M+75.0% | $6.8M+115% | $5.74M+99.0% | $4.82M+58.6% | $3.98M+27.6% | ||
| $18.71M+5.9% | $16.7M+3.4% | $21.62M+209% | $19.11M+155% | $17.66M+120% | ||
| -$18.71M-5.9% | -$16.7M-3.4% | -$21.62M-209% | -$19.11M-155% | -$17.66M-120% | ||
| -$14.98M+9.6% | -$13.72M+12.0% | -$19.44M-200% | -$17.31M-143% | -$16.57M-118% | ||
| -$18.71M-5.9% | -$16.7M-3.4% | -$21.62M-209% | -$19.11M-155% | -$17.66M-120% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Monopar Therapeutics profitable?
- Monopar Therapeutics is not currently profitable: it reported a net loss of $15.0M over the trailing twelve months.
- Where does Monopar Therapeutics's income statement data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.